Latanoprost (free acid)-d4
|
4物価
選択条件：
ブランド
- 富士フイルム和光純薬株式会社(wako)
パッケージ
- 50μg
- 100μg
- 500μg
- 1mg
- 生産者富士フイルム和光純薬株式会社(wako)
- 製品番号W01CAY316811
- 製品説明
- 英語製品説明Latanoprost (free acid)-d4
- 包装単位1mg
- 価格￥168800
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式会社(wako)
- 製品番号W01CAY316811
- 製品説明
- 英語製品説明Latanoprost (free acid)-d4
- 包装単位500μg
- 価格￥95500
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式会社(wako)
- 製品番号W01CAY316811
- 製品説明
- 英語製品説明Latanoprost (free acid)-d4
- 包装単位100μg
- 価格￥23500
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式会社(wako)
- 製品番号W01CAY316811
- 製品説明
- 英語製品説明Latanoprost (free acid)-d4
- 包装単位50μg
- 価格￥12300
- 更新しました2024-03-01
- 購入
| 生産者 | 製品番号 | 製品説明 | 包装単位 | 価格 | 更新時間 | 購入 |
|---|---|---|---|---|---|---|
| 富士フイルム和光純薬株式会社(wako) | W01CAY316811 | Latanoprost (free acid)-d4 |
1mg | ￥168800 | 2024-03-01 | 購入 |
| 富士フイルム和光純薬株式会社(wako) | W01CAY316811 | Latanoprost (free acid)-d4 |
500μg | ￥95500 | 2024-03-01 | 購入 |
| 富士フイルム和光純薬株式会社(wako) | W01CAY316811 | Latanoprost (free acid)-d4 |
100μg | ￥23500 | 2024-03-01 | 購入 |
| 富士フイルム和光純薬株式会社(wako) | W01CAY316811 | Latanoprost (free acid)-d4 |
50μg | ￥12300 | 2024-03-01 | 購入 |
プロパティ
貯蔵温度 :Hygroscopic, -20°C Freezer, Under inert atmosphere
溶解性 :Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
外見 :Oil to Gel
色 :Colorless.
溶解性 :Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
外見 :Oil to Gel
色 :Colorless.
安全情報
| 絵表示(GHS): |
 
|
||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 注意喚起語: | Danger | ||||||||||||||||||||||||||||||||||||||||
| 危険有害性情報: |
|
||||||||||||||||||||||||||||||||||||||||
| 注意書き: |
|
説明
Latanoprost (free acid)-d4 (Lat-FA-d4) contains four deuterium atoms at the 3, 3, 4, and 4 positions. It is intended for use as an internal standard for the quantification of Lat-FA by GC- or LC-mass spectrometry. Latanoprost is an F-series prostaglandin (PG) analog which has been approved for use as an ocular hypotensive drug. It is the isopropyl ester of a PGF2α analog containing an aromatic group (17-phenyl) in the ω-chain. As an isopropyl ester, latanoprost acts as a prodrug which is converted to Lat-FA by endogenous esterase enzymes. Lat-FA is a potent FP receptor agonist with an EC50 value of 3.6 nM for human FP receptors, which is twice the potency of PGF2α and more than 200 times more potent latanoprost. The efficacy of PG analog esters for the treatment of glaucoma correlates closely with the FP receptor binding affinity of the free acid. However, Lat-FA is more irritating and less effective than the prodrug latanoprost when applied directly to the eyes of human glaucoma patients.供給者とメーカー
Shanghai EFE Biological Technology Co., Ltd.
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
Hubei Xinyang Medical Technology Co., Ltd
Hubei Qingbei Yunyan Pharmaceutical Technology Co., Ltd
Henan Vcommend Consultrading Co., Ltd.
Hubei Moco Chemical Co., Ltd.
Cayman Chemical Company
Santa Cruz Biotechnology Inc
Aoki Biotechnology (Shenzhen) Co., Ltd.